Research Article | Open Access
Lijuan Sun, Qingqing Wu, Shi-Wen Jiang, Yani Yan, Xin Wang, Juan Zhang, Yan Liu, Ling Yao, Yuqing Ma, Li Wang, "Prenatal Diagnosis of Central Nervous System Anomalies by High-Resolution Chromosomal Microarray Analysis", BioMed Research International, vol. 2015, Article ID 426379, 9 pages, 2015. https://doi.org/10.1155/2015/426379
Prenatal Diagnosis of Central Nervous System Anomalies by High-Resolution Chromosomal Microarray Analysis
The aims of this study were to evaluate the contribution of chromosomal microarray analysis (CMA) in the prenatal diagnosis of fetuses with central nervous system (CNS) anomalies but normal chromosomal karyotype. A total of 46 fetuses with CNS anomalies with or without other ultrasound anomalies but normal karyotypes were evaluated by array-based comparative genomic hybridisation (aCGH) or single-nucleotide polymorphism (SNP) array. The result showed that CNVs were detected in 17 (37.0%) fetuses. Of these, CNVs identified in 5 (5/46, 10.9%) fetuses were considered to be likely pathogenic, and CNVs detected in 3 (3/46, 6.5%) fetuses were defined as being of uncertain clinical significance. Fetuses with CNS malformations plus other ultrasound anomalies had a higher rate of pathogenic CNVs than those with isolated CNS anomalies (13.6% versus 8.3%), but there was no significant difference (Fisher’s exact test, ). Pathogenic CNVs were detected most frequently in fetuses with Dandy-Walker syndrome (2/6, 33.3%) when compared with other types of neural malformations, and holoprosencephaly (2/7, 28.6%) ranked the second. CMA is valuable in prenatal genetic diagnosis of fetuses with CNS anomalies. It should be considered as part of prenatal diagnosis in fetuses with CNS malformations and normal karyotypes.
The prevalence of CNS abnormalities is 0.14–0.16% in live births and reaches as high as 3–6% in stillbirths . CNS anomalies are a group of serious birth defects associated with high rates of infant death or disability. In addition to their threat to life, CNS malformations cause enormous direct and indirect health costs . While the etiology of fetal central nervous system anomalies is highly heterogeneous, genetic conditions are recognized as a major cause [3, 4]. The significance of genetic mutations is also underscored by the fact that many environmental factors lead to CNS malformations through their mutagenic effects. Studies have shown that CNS malformations detected by ultrasonography were strongly associated with chromosomal abnormalities, especially trisomy 13 and 18 [5, 6]. However, there remains a dilemma in prenatal diagnosis of fetuses who have CNS anomalies, either with or without other organ abnormalities, but have normal karyotypes.
Conventional chromosome karyotype analysis such as G-Banding has been the standard method for the detection of a wide range of chromosomal abnormalities in the past decades. However, this technique is limited to the detection of chromosomal alterations larger than 5 Mb, and submicroscopic duplications and deletions, which are often associated with mental retardation (MR) and malformations, are not detectable by conventional karyotyping .
Chromosomal microarray analysis (CMA) allows the detection of microdeletions and microduplications that are not routinely seen on karyotyping . It is possible to evaluate the entire genome for DNA CNVs, as small as 50–100 kb, which is equal to a 100-fold magnification in resolution compared with karyotyping [9, 10]. This high-resolution analysis of DNA CNVs, initially applied to cancer studies, has subsequently been extended to postnatal diagnosis of various congenital anomalies and MR. Recent studies have focused specifically on the use of microarray analysis in prenatal diagnosis of fetuses with abnormal ultrasound findings [8, 11, 12], especially on the concerns regarding the relationship between CNVs and congenital heart diseases (CHD) [13, 14]. Application of CMA to identify submicroscopic chromosomal aberrations in fetuses with CNS anomalies has been poorly described in the literature so far.
The aims of this study were to evaluate the utility of CMA for prenatal diagnosis of fetuses with CNS anomalies detected by ultrasound but normal karyotypes and to explore the CNVs in fetuses carrying different types of CNS malformations.
2. Materials and Methods
2.1. Subject Selection and Ultrasound Findings
From December 2011 to June 2014, 31,802 pregnant women were referred to the Department of Obstetrics and Fetal-Maternal Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China, for routine anomaly scan. 46 fetuses were diagnosed for CNS abnormalities, with or without other associated anomalies by transabdominal ultrasonography, showing normal karyotypes in conventional G-band karyotype analysis. Of these 46 primary study subjects, in 24 the CNS anomalies were isolated and 22 fetuses with CNS malformations were associated with other abnormalities. This study was approved by the local Ethics Committee of the Capital Medical University. Written informed consent to participate in the study was obtained from each patient.
2.2. CMA Methods
Umbilical cord blood samples were collected from the 46 pregnant women between 21 and 27 gestational weeks by cordocentesis. Of the 46 samples, 30 cases (65.2%) were examined with array-based comparative genomic hybridisation (aCGH), and then additional 16 cases (34.8%) were tested with single-nucleotide polymorphism (SNP) array in consideration of the advantages for SNP detecting copy number aberrations  after being approved by Food and Drug Administration (FDA). Genomic DNA was extracted from 2 mL of umbilical cord blood with a commercially available Blood Genomic DNA Extraction kit (BioChain Institute Inc., Newark, CA or Yuanpinghao Biotech Co., Ltd., resp.) according to the manufacturer’s instructions. aCGH was performed using K oligonucleotide-based microarray (Agilent), and SNP array was detected using a 750 K microarray (Affymetrix CytoScan 750 K Array). After hybridization, a laser scanner was used for scanning the arrays, and the data was analyzed with the use of special software package (Workbench and Chromosome Analysis Suite).
2.3. The Interpretation for CMA Results
To interpret the results, we compared all detected copy number gains or losses with known CNVs listed in publically available databases (DECIPHER Database (http://decipher.sanger.ac.uk/), Online Mendelian Inheritance in Man (OMIM, http://omim.org/), PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), and the Database of Genomic Variants (DGV, http://www.ncbi.nlm.nih.gov/dbvar/). For all CNVs, CMA results were interpreted independently of any previous cytogenetic findings.
2.4. Statistical Analysis
Statistical analysis of data was performed using SPSS version 17.0. Bivariate analysis was carried out using Fisher’s exact test (two-tailed). was considered statistically significant.
3.1. CNVs Detection Rates
Of the 46 study subjects, CNVs were detected in 17 (37.0%) cases, whereas no deletion or duplication was found in the remaining 29 cases (63.0%). Pathogenic CNVs were identified in 5 (10.9%) fetuses including 2 cases with isolated CNS malformations and 3 cases associated with other organ abnormalities. In addition, CNVs of uncertain clinical significance were detected in 3 (6.5%) fetuses, and CNVs identified in 9 (19.6%) fetuses were considered to be likely benign and of no clinical significance. Fetuses with CNS malformations plus other ultrasound anomalies had a seemingly higher detection rate than those with isolated CNS anomalies (13.6% versus 8.3%), but the difference did not reach a statistically significant level (Fisher’s exact test, ) (Table 1).
|One (Case 7) of 10 fetuses with cardiovascular abnormalities was also associated with facial anomaly, but only in the row of cardiovascular system.|
The fetus (Case 4) was associated with skeletal dysplasia and lip and palate cleft, but only in the row of musculoskeletal system.
3.2. CMA Results for 5 Fetuses with Pathogenic CNVs and 3 Cases with CNVs of Uncertain Clinical Significance
|GA, gestational weeks; VSD, ventricular septal defect; PLSVC, persistent left superior vena cava; NF, nuchal fold; IUGR, intrauterine growth retardation.|
Human genome build was hg19.
Of the 24 fetuses with isolated CNS anomalies, pathogenic CNVs were identified in 2 cases (2/24, 8.3%) (Table 2, Cases 1 and 2) as follows.
(1) Case 1 was a fetus with holoprosencephaly and single nostril on prenatal ultrasound. Sonographic abnormal findings were shown in Figure 3 and confirmed by the autopsy pathology. The microarray analysis result showed a 3.44-Mb deletion within the chromosome 7q36.3, encompassing the sonic hedgehog (SHH) gene (Table 2, Figure 1(a)). Deletions SHH gene are known to be related to holoprosencephaly  (OMIM ID: ).
(2) Case 2 harbored a 3.15-Mb duplication in chromosome 22q11.21 (Table 2, Figure 2(a)) which included 43 OMIM genes such as TBX1 in a fetus with hydrocephaly. The CMA result has been associated with 22q11.2 microduplication syndrome (OMIM ID: #608363). Dupont et al. reported that 22q11.2 microduplication syndrome was characterized by a highly variable clinical phenotypes, ranging from apparently normal or slightly dysmorphic features to severe malformations with profound mental retardation . Neurological features of the syndrome included intellectual or learning disability, motor delay, and other neurodevelopmental disorders . In this case, the parents chose termination of pregnancy (TOP) because of fetal hydrocephaly that was confirmed by postnatal imaging.
Information for clinically significant CNVs detected in 3/22 (13.6%) fetuses with CNS anomalies as well as other abnormalities (Table 2, Cases 3–5) was as follows.
(1) Case 3 was a fetus with Dandy-Walker malformation in association with ventricular septal defect and persistent left superior vena cava. The microarray test result revealed a 3.25-Mb deletion in chromosome 2q13–q14.1 that included four OMIM genes (Table 2, Figure 1(b)): PAX8, IL1B, MERTK, and IL1RN. As reported by Kasai and Narahara, these genes were associated with neurodevelopmental impairment, congenital heart defects, and facial and finger malformations . The parents chose TOP because of the sonographic abnormalities that were confirmed by autopsy.
(2) Case 4 carried a 0.17-Mb deletion in chromosome Xq13.3 (Table 2, Figure 2(b)) which involved the ABC7 gene (OMIM ID: ) in a male fetus with Dandy-Walker syndrome (cerebellar malformation), absence of septum pellucidum, and arachnoid cyst associated with lip and palate cleft and skeletal dysplasia. Bekri et al.  previously identified a missense mutation in the ABC7 gene to be the cause of X-linked sideroblastic anemia with cerebellar ataxia. Although it is not experimentally confirmed, we considered that the microdeletion might be responsible for fetal cerebellar malformation. The parents opted for TOP because of abnormal sonographic findings which were confirmed by autopsy pathology.
(3) Case 5 was a fetus with holoprosencephaly (HPE) associated with lip and palate cleft. The microarray test discovered a 0.34-Mb deletion within 2p21 (Table 2, Figure 2(c)) which harbors SIX3 gene (OMIM ID: ). It has been reported that molecular evaluation of foetuses with holoprosencephaly showed high incidence of microdeletions in four HPE genes, one of which was SIX3 gene . Lacbawan et al. reported that SIX3 mutations could result in relatively severe holoprosencephaly . The parents had chosen TOP because of the severe malformations detected by prenatal ultrasound which were confirmed by autopsy.
Our study covered 3 fetuses with the CNVs of uncertain clinical significance (Table 2, Cases 6–8) as the follows.
(1) Case 6 was originally referred for prenatal cytogenetic diagnosis because of exencephaly detected by ultrasonography. Following negative findings in fetal karyotype analysis, CMA result revealed a deletion of 4.03 Mb in chromosome 19p12p13.11 (Table 2, Figure 1(c)). The region contained a lot of segmental duplications and many homologous genes, such as ZNF family that probably mediated the recombination giving rise to the deletion. However, extensive literature search failed to identify that any gene in the relevant region might cause known syndromes. Both parents showed negative CMA results, indicating that the deletion was de novo. Thus, the clinical significance of this CNV was uncertain. The family opted for TOP because of the severe ultrasonography results. The patient underwent Rivanol amniocentesis induction of labor with an informed consent, and the autopsy pathology confirmed the ultrasound diagnosis.
(2) Case 7 was referred because of holoprosencephaly in association with facial anomaly and ventricular septal defect as ultrasonographic findings. There was a 2.79-Mb deletion in chromosome 4q35.2 (Table 2, Figure 1(d)), with proximal breakpoint located 300 kb upstream the OMIM gene FAT1. This gene encodes a tumor suppressor essential for controlling cell proliferation during Drosophila development . The gene product is a member of the cadherin superfamily and is expressed at high levels in a number of fetal epithelia. Its product probably functions as an adhesion molecule and/or signaling receptor and is likely to be important in developmental processes and cell communication. We think that it is possible for the microdeletion to influence FAT1 gene expression by position effect because of the near distance. The CMA results from both of parents were negative, indicating a de novo mutation. So the clinical significance of the CNVs in this case remained unclear. The parents chose TOP, and the abnormal ultrasound findings were confirmed by autopsy pathology.
(3) Case 8 was a fetus with hydrocephaly associated with sacrococcygeal vertebral anomaly, intrauterine growth retardation (IUGR), and thickened nuchal fold (NF) on prenatal ultrasound. The array test result showed a 1.15-Mb deletion in chromosome 21q21.1 (Table 2, Figure 2(d)) which contained most of the NCAM2 gene. It has been reported that NCAM2 was a candidate for involvement in certain Down syndrome phenotypes . However, the role of NCAM2 deletion in the pathophysiology of Down syndrome is unknown. CMA on both parents was negative, pointing to a possibility for de novo mutation. The clinical significance of this CNV was considered to be uncertain. The pregnant woman underwent TOP, and the autopsy pathology confirmed the ultrasonographic findings.
3.3. The Types of Fetal CNS Anomalies and Pathogenic CNVs Incidence
The relationship between the different types of CNS anomalies and the incidence of fetuses with pathogenic CNVs is shown in Table 3. We found that clinically significant CNVs were detected most frequently in fetuses with Dandy-Walker syndrome (2/6, 33.3%), and holoprosencephaly (2/7, 28.6%) ranked the second.
In the past few years, CMA has been extensively used to investigate chromosomal aberrations in the postnatal population with unexplained neurodevelopmental disorders including developmental delay/intellectual disability, autism spectrum disorders, and multiple congenital anomalies [25–27]. A recent meta-analysis  of CMA on 13,926 postnatal subjects in whom conventional cytogenetic tests have proven negative reported an overall diagnostic rate of 10% for pathogenic genomic imbalances in such populations.
Recently results on application of CMA for prenatal diagnosis have also been published. D’Amours et al.  reported a 8.2% detection rate of pathogenic CNVs in fetuses with major malformations and a normal karyotype by aCGH. A meta-analysis conducted by Hillman et al.  indicated that CMA had a 5.2% additive value compared with conventional karyotyping. Collectively, these studies suggested that CMA was able to identify additional, clinically significant cytogenetic information in fetuses with various kinds of structural anomalies and a normal karyotype. The efforts to diagnose fetuses with CNS malformations with or without other structural abnormalities in our study represent a further attempt for the usage of this powerful technique in prenatal genetic tests.
In our study we focused on fetuses with CNS malformations and an apparently normal karyotype, and the results showed that 10.9% of fetuses had submicroscopic chromosomal abnormalities which were likely to be pathological. This suggests that the microarray technique is able to provide additional information in fetuses with CNS malformations and a normal karyotype. Such information could lead to better prenatal consultation and the assessment of the recurrent risk. Compared with the studies of D’Amours et al.  and Hillman et al. , this project achieved a higher detection rate (10.9%) of pathogenic CNVs. The elevated detection rate could be attributed to the exclusion of congenital non-CNS anomalies in this study. It should be pointed out that the sample size of this study was relatively small, which could limit the extrapolation of our observations. Further investigations in larger cohorts need to be conducted to validate the potentially benefits of CMA.
In this study we found that the detection rates of pathogenic CNVs in various types of CNS anomalies were different. It was noteworthy that fetuses with Dandy-walker syndrome (2/6, 33%) emerged to be most frequently associated with submicroscopic chromosomal abnormalities among various congenital neural abnormalities when karyotyping showed normal results. There were a few reports [29, 30] regarding CNVs of Dandy-Walker malformation, such as deletion in chromosomes 13q and 7p, which were different from deletion in chromosomes 2q and Xq in this study. Our results also indicated holoprosencephaly (2/7, 28.6%) as the second common malformation associated with pathogenic CNVs among all types of CNS abnormalities. This observation provides some insights into the pathogenesis of holoprosencephaly in fetuses with a normal karyotype, suggesting that CNVs could be a significant cause of this specific type of CNS abnormalities. Shaffer et al.  performed a retrospective analysis of pathogenic CNVs detection rate by CMA for 2858 pregnancies with different organ system abnormalities and normal karyotypes and found that both of posterior fossa defects (including Dandy-Walker syndrome and cerebellar hypoplasia) and holoprosencephaly had the highest detection rates of clinically significant CNVs (14.6% and 10.6%) among various types of CNS anomalies, which was similar to our results.
Clinically significant CNVs were detected in 3 fetuses with nervous system anomalies plus other congenital structural malformations, one case with cardiovascular defect, one with lip and palate cleft, and another one with skeletal dysplasia and lip and palate cleft. Fetuses with CNS malformations plus other ultrasound anomalies had a higher detection rate than those with isolated CNS anomalies (13.6% versus 8.3%), but there were no significant differences in the incidence of pathogenic CNVs between them (Fisher’s exact test, ). Our results are comparable with the study reported by Shaffer et al. , who found the detection rate of clinical significant CNVs was 6.5% in fetuses with a single CNS anomaly while 11% in cases with CNS malformations and other abnormalities.
Although chromosomal microarray techniques could offer several advantages including high-resolution, whole genome analysis, and a short turnaround time (about 48 h after DNA extraction) in comparison with conventional chromosomal karyotyping, it cannot identify balanced translocations or low level of mosaicism. Therefore, prenatal consultations should not rely on the results of CMA alone, and conventional chromosomal karyotyping and prenatal ultrasound diagnosis should also be required. The present results substantiated that CMA may be especially valuable in routine prenatal diagnosis when fetuses with abnormal ultrasound findings but normal karyotypes.
Our results have shown that CMA is a valuable diagnostic tool in prenatal genetic diagnosis of CNS anomalies. Our data indicated that assessment of submicroscopic chromosomal aberrations by CMA should be undertaken in fetuses with CNS anomalies and a normal karyotype. This finding not only provides information for clinical consultation but may also allow more accurate genetic diagnosis and a better understanding of the etiology and mechanisms involved in the congenital defects.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors would like to express their great appreciation to Be Creative Lab (Beijing) for technical assistance. This research was supported by Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support, Code: XMLX201310, Beijing Natural Science Foundation (Grant no. 7142026), and Beijing Municipal Science & Technology Commission (no. Z141107002514006).
- D. Onkar, P. Onkar, and K. Mitra, “Evaluation of fetal central nervous system anomalies by ultrasound and its anatomical co-relation,” Journal of Clinical and Diagnostic Research, vol. 8, no. 6, pp. AC05–AC07, 2014.
- Ministry of Health of the People’s Republic of China and Disabled Persons Federation of China, “Promote birth population quality and reduce birth deficiency and deformity action plan of China (2002–2010),” Maternal Child Health Care of China, vol. 17, pp. 648–651, 2002.
- J. Huang, I. Y. M. Wah, R. K. Pooh, and K. W. Choy, “Molecular genetics in fetal neurology,” Seminars in Fetal and Neonatal Medicine, vol. 17, no. 6, pp. 341–346, 2012.
- F. Petracchi, L. Crespo, C. Michia, L. Igarzabal, and E. Gadow, “Holoprosencephaly at prenatal diagnosis: analysis of 28 cases regarding etiopathogenic diagnoses,” Prenatal Diagnosis, vol. 31, no. 9, pp. 887–891, 2011.
- K. R. Goetzinger, D. M. Stamilio, J. M. Dicke, G. A. Macones, and A. O. Odibo, “Evaluating the incidence and likelihood ratios for chromosomal abnormalities in fetuses with common central nervous system malformations,” The American Journal of Obstetrics and Gynecology, vol. 199, no. 3, pp. 285.e1–285.e6, 2008.
- S. Pitukkijronnakorn, P. Promsonthi, P. Panburana, R. Rangsiprakarn, and A. Chittacharoen, “Prenatal ultrasonographic findings in ‘trisomy 13’,” Journal of the Medical Association of Thailand, vol. 91, no. 11, pp. 1651–1655, 2008.
- P. Evangelidou, C. Sismani, M. Ioannides et al., “Clinical application of whole-genome array CGH during prenatal diagnosis: study of 25 selected pregnancies with abnormal ultrasound findings or apparently balanced structural aberrations,” Molecular Cytogenetics, vol. 3, article 24, 2010.
- R. J. Wapner, C. L. Martin, B. Levy et al., “Chromosomal microarray versus karyotyping for prenatal diagnosis,” The New England Journal of Medicine, vol. 367, no. 23, pp. 2175–2184, 2012.
- T.-H. Bui, A. Vetro, O. Zuffardi, and L. G. Shaffer, “Current controversies in prenatal diagnosis 3: is conventional chromosome analysis necessary in the post-array CGH era?” Prenatal Diagnosis, vol. 31, no. 3, pp. 235–243, 2011.
- J. M. Friedman, “High-resolution array genomic hybridization in prenatal diagnosis,” Prenatal Diagnosis, vol. 29, no. 1, pp. 20–28, 2009.
- E. M. Vestergaard, R. Christensen, O. B. Petersen, and I. Vogel, “Prenatal diagnosis: array comparative genomic hybridization in fetuses with abnormal sonographic findings,” Acta Obstetricia et Gynecologica Scandinavica, vol. 92, no. 7, pp. 762–768, 2013.
- G. D'Amours, Z. Kibar, G. Mathonnet et al., “Whole-genome array CGH identifies pathogenic copy number variations in fetuses with major malformations and a normal karyotype,” Clinical Genetics, vol. 81, no. 2, pp. 128–141, 2012.
- C. Liao, R. Li, F. Fu et al., “Prenatal diagnosis of congenital heart defect by genome-wide high-resolution SNP array,” Prenatal Diagnosis, vol. 34, no. 9, pp. 858–863, 2014.
- Y. Yan, Q. Wu, and L. Zhang, “Detection of submicroscopic chromosomal aberrations by array-based comparative genomic hybridization in fetuses with congenital heart disease,” Ultrasound in Obstetrics & Gynecology, vol. 43, no. 4, pp. 404–412, 2014.
- X. Xu, E. B. Johnson, L. Leverton et al., “The advantage of using SNP array in clinical testing for hematological malignancies-a comparative study of three genetic testing methods,” Cancer Genetics, vol. 206, no. 9-10, pp. 317–326, 2013.
- K. Taniguchi, A. E. Anderson, A. E. Sutherland, and D. Wotton, “Loss of tgif function causes holoprosencephaly by disrupting the SHH signaling pathway,” PLoS Genetics, vol. 8, no. 2, Article ID e1002524, 2012.
- C. Dupont, F. R. Grati, K. W. Choy et al., “Prenatal diagnosis of 24 cases of microduplication 22q11.2: an investigation of phenotype-genotype correlations,” Prenatal Diagnosis, vol. 35, no. 1, pp. 35–43, 2015.
- G. Valvo, F. Novara, P. Brovedani et al., “22q11.2 Microduplication syndrome and epilepsy with continuous spikes and waves during sleep (CSWS). A case report and review of the literature,” Epilepsy and Behavior, vol. 25, no. 4, pp. 567–572, 2012.
- R. Kasai and K. Narahara, “Proximal 2q monosomy in a case with mild phenotype,” Teratology, vol. 38, pp. 529–530, 1988.
- S. Bekri, G. Kispal, H. Lange et al., “Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation,” Blood, vol. 96, no. 9, pp. 3256–3264, 2000.
- C. Bendavid, C. Dubourg, I. Gicquel et al., “Molecular evaluation of foetuses with holoprosencephaly shows high incidence of microdeletions in the HPE genes,” Human Genetics, vol. 119, no. 1-2, pp. 1–8, 2006.
- F. Lacbawan, B. D. Solomon, E. Roessler et al., “Clinical spectrum of SIX3-associated mutations in holoprosencephaly: correlation between genotype, phenotype and function,” Journal of Medical Genetics, vol. 46, no. 6, pp. 389–398, 2009.
- J. Dunne, A. M. Hanby, R. Poulsom et al., “Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule,” Genomics, vol. 30, no. 2, pp. 207–223, 1995.
- A. Paoloni-Giacobino, H. Chen, and S. E. Antonarakis, “Cloning of a novel human neural cell adhesion molecule gene (NCAM2) that maps to chromosome region 21q21 and is potentially involved in Down syndrome,” Genomics, vol. 43, no. 1, pp. 43–51, 1997.
- D. T. Miller, M. P. Adam, S. Aradhya et al., “Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies,” The American Journal of Human Genetics, vol. 86, no. 5, pp. 749–764, 2010.
- G. S. Sagoo, A. S. Butterworth, S. Sanderson, C. Shaw-Smith, J. P. T. Higgins, and H. Burton, “Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects,” Genetics in Medicine, vol. 11, no. 3, pp. 139–146, 2009.
- R. Hochstenbach, E. van Binsbergen, J. Engelen et al., “Array analysis and karyotyping: Workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands,” European Journal of Medical Genetics, vol. 52, no. 4, pp. 161–169, 2009.
- S. C. Hillman, S. Pretlove, A. Coomarasamy et al., “Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis,” Ultrasound in Obstetrics and Gynecology, vol. 37, no. 1, pp. 6–14, 2011.
- M. Mimaki, T. Shiihara, M. Watanabe et al., “Holoprosencephaly with cerebellar vermis hypoplasia in 13q deletion syndrome: critical region for cerebellar dysgenesis within 13q32.2q34,” Brain & Development, 2014.
- C. Liao, F. Fu, R. Li et al., “Dandy-walker syndrome and microdeletions on chromosome 7,” Zhonghua Yi Xue Yi Chuan Xue Za Zhi, vol. 29, no. 1, pp. 48–51, 2012.
- L. G. Shaffer, J. A. Rosenfeld, M. P. Dabell et al., “Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound,” Prenatal Diagnosis, vol. 32, no. 10, pp. 986–995, 2012.
Copyright © 2015 Lijuan Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.